These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18490647)

  • 21. Trastuzumab/navelbine produces encouraging results in early breast cancer patients.
    Oncology (Williston Park); 2003 Sep; 17(9):1224. PubMed ID: 14569850
    [No Abstract]   [Full Text] [Related]  

  • 22. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
    Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
    Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Novel targeting therapy concept for breast cancer treatment].
    Toi M
    Nihon Yakurigaku Zasshi; 2008 Sep; 132(3):177-9. PubMed ID: 18787301
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety and efficacy of neo-adjuvant sequential dose-dense chemotherapy doublets combined with trastuzumab in patients with HER-2-positive early stage breast cancer.
    Sánchez-Muñoz A; García-Tapiador AM; Dueñas-García R; Jaén-Morago A; Ortega-Granados AL; Martínez-Ortega E; Fernández Morales M; Fernández-Navarro M; de la Torre Cabrera C; Dueñas B; Ureña C; Martínez J; Morales F; Ramírez-Tortosa C; Sánchez-Rovira P
    Breast J; 2008; 14(5):506-7. PubMed ID: 18705667
    [No Abstract]   [Full Text] [Related]  

  • 26. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.
    Saura C; Bendell J; Jerusalem G; Su S; Ru Q; De Buck S; Mills D; Ruquet S; Bosch A; Urruticoechea A; Beck JT; Di Tomaso E; Sternberg DW; Massacesi C; Hirawat S; Dirix L; Baselga J
    Clin Cancer Res; 2014 Apr; 20(7):1935-45. PubMed ID: 24470511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting c-erbB2 and other receptors of the c-erbB family: rationale and clinical applications.
    Bianco AR
    J Chemother; 2004 Nov; 16 Suppl 4():52-4. PubMed ID: 15688610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Biweekly docetaxel and weekly trastuzumab treatment in HER 2-overexpressing metastatic breast cancer patients].
    Kagawa N; Fukuda Y; Arai H; Sasada T; Yamashita M; Komekami Y; Matsugu Y; Nakahara H; Tanaka T
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1081-5. PubMed ID: 16912526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hints of future progress for HER-2 breast cancer.
    Twombly R
    J Natl Cancer Inst; 2011 Apr; 103(7):535-7. PubMed ID: 21436059
    [No Abstract]   [Full Text] [Related]  

  • 30. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
    Burstein HJ; Sun Y; Dirix LY; Jiang Z; Paridaens R; Tan AR; Awada A; Ranade A; Jiao S; Schwartz G; Abbas R; Powell C; Turnbull K; Vermette J; Zacharchuk C; Badwe R
    J Clin Oncol; 2010 Mar; 28(8):1301-7. PubMed ID: 20142587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trastuzumab trials steal show at ASCO meeting.
    Tuma RS
    J Natl Cancer Inst; 2005 Jun; 97(12):870-1. PubMed ID: 15956644
    [No Abstract]   [Full Text] [Related]  

  • 32. [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
    Ismaili N; Belbaraka R; Elomrani A; Khouchani M; Tahri A
    Presse Med; 2013 Nov; 42(11):1461-8. PubMed ID: 23721860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
    Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
    Hamberg P; Bos MM; Braun HJ; Stouthard JM; van Deijk GA; Erdkamp FL; van der Stelt-Frissen IN; Bontenbal M; Creemers GJ; Portielje JE; Pruijt JF; Loosveld OJ; Smit WM; Muller EW; Schmitz PI; Seynaeve C; Klijn JG;
    Clin Breast Cancer; 2011 Apr; 11(2):103-13. PubMed ID: 21569996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Addition of trastuzumab to chemotherapy produces 50% increase in survival in patients selected by FISH.
    Oncology (Williston Park); 2001 Oct; 15(10):1345, 1364. PubMed ID: 11702961
    [No Abstract]   [Full Text] [Related]  

  • 36. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
    Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular mechanisms in signal transduction: new targets for the therapy of gynecologic malignancies.
    Gabriel B; Fischer DC; Kieback DG
    Onkologie; 2002 Jun; 25(3):240-7. PubMed ID: 12119458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab.
    Eniu A
    J BUON; 2007 Sep; 12 Suppl 1():S119-26. PubMed ID: 17935269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).
    Guarneri V; Frassoldati A; Piacentini F; Jovic G; Giovannelli S; Oliva C; Conte P
    Clin Breast Cancer; 2008 Apr; 8(2):192-4. PubMed ID: 18621618
    [No Abstract]   [Full Text] [Related]  

  • 40. Antibodies as molecular target-based therapy: trastuzumab.
    Tokuda Y
    Int J Clin Oncol; 2003 Aug; 8(4):224-9. PubMed ID: 12955577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.